KORONER ARTER HASTALIĞINDA DOĞRU ANTİPLATELET SEÇİMİ

Year 2024, Volume: 4 Issue: 9, 32 - 39, 07.02.2024

Mustafa Yurtdaş Mahmut Özdemir

https://doi.org/10.54270/atljm.2023.42

Abstract

Koroner arter hastalığı yaygın bir kardiyovasküler hastalıktır. Antiplatelet tedavi, koroner arter hastalığının tüm formlarında, özellikle de perkütan koroner girişim uygulanan hastalarda tedavinin temel taşıdır. Güncel antiplatelet tedavi, aterotrombotik komplikasyonların önlenmesinde yüksek düzeyde etkilidir. Kanama riskini artırmadan aterotrombotik olayları daha iyi önleyici özelliklere sahip hem oral hem iv yeni antiplatelet ilaçlar klinik kullanıma girmiştir. Bu makalenin amacı, soru-cevap tarzında oral ve intravenöz antiplatelet ajanların kullanımı hakkında güncel bilgiler sunmaktır.

Keywords

antiplatelet, koroner arter hastalığı, stentleme, iskemi, oral

References

• Ndrepepa G, Berger PB, Mehilli J, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008;51:690-7.
• https://www.medscape.org (Son erişim tarihi: 24.09.2023)
• Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;15:357:2001-15.
• Wallentin L, Becker RC, Budaj A, et al; PLATO Investigators; Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
• Johannesen K, Siverskog J, Henriksson M, et al. Implementation of Ticagrelor Reduced Mortality in Routine Clinical Care: Evidence From a Natural Experiment Including 109 995 Patients With Myocardial Infarction in Sweden. J Am Heart Assoc 2023;12:e027384.
• Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145:e18-e114.
• Byrne RA, Rossello X, Coughlan JJ, et al; ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 2023 Aug 25:ehad191. doi: 10.1093/eurheartj/ehad191. Epub ahead of print.
• Angiolillo DJ, Rollini F, Storey RF, et al. International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies. Circulation 2017;136:1955-75.
• De Luca L, Steg PG, Bhatt DL, et al. Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives. J Am Heart Assoc 2021;10:e022125.
• Bhatt DL, Stone GW, Mahaffey KW, et al; CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013;368:1303-13.
• Tavenier AH, Hermanides RS, Ottervanger JP, et al; ON-TIME 3 investigators. Impact of vomiting on P2Y12 platelet inhibition in patients with ST-elevation myocardial infarction: A prespecified subanalysis of the ON-TIME 3 trial. Am Heart J 2022;243:39-42.
• Franchi F, Rollini F, Rivas A, et al. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation 2019;139:1661-70.
• Yusuf S, Zhao F, Mehta SR, et al; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
• Montalescot G, Bolognese L, Dudek D, et al; ACCOAST Investigators. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 2013;369:999-1010.
• Tarantini G, Mojoli M, Varbella F, et al; DUBIUS Investigators; Italian Society of Interventional Cardiology. Timing of Oral P2Y12 Inhibitor Administration in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. J Am Coll Cardiol 2020;76:2450-9.
• Zeymer U, Arntz HR, Mark B, et al. Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. Clin Res Cardiol 2012;101:305-12.
• Montalescot G, van 't Hof AW, Lapostolle F, et al; ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 2014 ;371:1016-27.
• Neumann FJ, Sousa-Uva M, Ahlsson A, et al; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019;40:87-165.
• Sullivan AE, Nanna MG, Wang TY, et al. Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention: JACC Review Topic of the Week. J Am Coll Cardiol 2021;78:1550-63.
• Yerasi C, Case BC, Chezar-Azerrad C, et al. Cangrelor vs. glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention. Am Heart J 2021;238:59-65.